Challenges Of Moving A Bioconjugate Candidate From Clinic To Market

Source: Lonza

A novel drug’s path to market is complex and uncertain. Drug developers must successfully navigate the journey, under the growing pressure of regulation and competition, and while carefully managing technical and financial risk.

Beyond the challenges of gaining regulatory approval, transitioning production and scaling up from a clinical to commercial scale, and planning for the capacity to meet market demand, going to market with a bioconjugate or ADC candidate involves additional complexity. These biotherapeutics comprise multiple, different components, so their manufacturing and highly complex supply chains require specific know-how and capabilities to succeed in commercial settings.

In this webinar, we explore the particular challenges when moving a bioconjugate candidate from clinic to market. Our experts share key considerations and pitfalls to avoid along the way. Several customer case studies will illustrate concrete solutions about how Lonza’s expertise and integrated solutions have helped drug developers bring their innovative therapeutics to market.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online